time

[키워드] 1:1 a BTK inhibitor Acalabrutinib adaptive added adjusted agent Amendment analyses Analysis Anti-viral approval Arm baseline bemcentinib Blinding block BTK inhibitor candidate Candidates cause caused changed clinical Clinical characteristics Clinical improvement clinically comparator complement COVID COVID-19 current Day discharge disease dissemination dropped Efficacy element Endpoint England estimation EudraCT evaluate Evidence evidence of experimental arm GRADE group help heparin hospital hospitalised include Inflammatory response inhibitor Ireland IRT Mask Master protocol Mild Mild disease monoclonal antibody Multiple nasal prongs National non-invasive ventilation number objective open open label Ordinal Scale outcome oxygen Oxygen therapy oxygen therapy) participant Patient performed Phase 2 phase II platform proceed protocol protocols provide randomisation randomised randomised controlled randomised controlled trial randomization recruited recruitment reduce Registered Regulatory reported Respiratory failure response response rate Safety Sample size SARS-COV-2 infection SARS-CoV-2 spike SARS-CoV-2 spike protein seamless selected severity shown SOC Spike protein Stage stage 2 stages Standard of care status stratified Study protocol sustained Task Force technology the spike protein the WHO therapy time treat Treatment treatment of COVID-19 Trial Trial registration Viral viral infection virus website with COVID-19 working zilucoplan
[DOI] 10.1186/s13063-020-04584-9 PMC 바로가기 [Article Type] Letter